Takako Eguchi Nakajima

Author

Also Known As

Keiko Murofushi, Nakajima, T.E., T E Nakajima, T NAKAJIMA, T Nakajima, T. E. Nakajima, T. Eguchi Nakajima, T. Nakajima, T.E. Nakajima, T.Eguchi Nakajima

335

Publications

12.7K

Citations

H-Index

107

Concepts

All Affiliations

Niigata University St. Marianna University School of Medicine National Cancer Center Hospital East Aichi Cancer Center Niigata University Medical and Dental Hospital

About

Takako Eguchi Nakajima is an author at Niigata University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	55	5.1K
2	Health Sciences	8	8	697
3	Allergy	6	6	364
4	Natural Sciences	1	1	11
5	Public Health	1	1	1.9K

Takako Eguchi Nakajima

124

Publications

9.5K

Citations

H-Index

Page 1

	Year	Citations
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer Yojiro Hashiguchi, Kei Muro, Yutaka Saitō, International Journal of Clinical Oncology Japanese SocietySurgical OncologyCancer ManagementGastroenterologySurgery	2019	1.9K
T-Cell–Mediated Lysis of Endothelial Cells in Acute Coronary Syndromes Takako Eguchi Nakajima, Stephanie Schulte, Kenneth J. Warrington, Circulation	2002	357
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda, Nature Medicine Scrum-japan Gi-screenOncologyGastrointestinal OncologyTumor HeterogeneityClinical Utility	2020	347
Major Histocompatibility Complex Class I–Recognizing Receptors Are Disease Risk Genes in Rheumatoid Arthritis Jeng‐Hsien Yen, Brenda E. Moore, Takako Eguchi Nakajima, The Journal of Experimental Medicine	2001	335
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Kei Muro, Florian Lordick, Takahiro Tsushima, Annals of Oncology	2018	284
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) K. Yamazaki, Michitaka Nagase, H Tamagawa, Annals of Oncology Gastrointestinal OncologyMedicinePharmacologyColorectal CancerPathology	2016	274
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer Takako Eguchi Nakajima, Yasuhide Yamada, Tetsutaro Hamano, Cancer Science Colorectal AdenomaChemoprevention StrategyPathologyAdiponectin LevelAdipokines	2010	222
Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system Keisuke Sato, Naoki Takahashi, Tamotsu Kato, Scientific Reports	2017	193
Effect of periodontal treatment on the C‐reactive protein and proinflammatory cytokine levels in Japanese periodontitis patients Kazuhisa Yamazaki, Tomoyuki Honda, Taro Oda, Journal of Periodontal Research	2004	188
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer Takako Eguchi Nakajima, Yasuhide Yamada, Tetsutaro Hamano, Journal of Gastroenterology ObesityMetabolic SyndromeMedicineAdipocytokine LevelsImmunology	2009	179

Page 1